uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that seven presentations, of which one is an oral presentation, will be delivered at the upcoming congress of the European Association for Haemophilia and Allied Disorders (EAHAD), held in The Hague, the Netherlands, February 5 - 7, 2020.

Specific details on uniQure's presentations at EAHAD include:  

  • Title: One Year Data from A Phase 2b Trial Of AMT-061 (AAV5-Padua hFIX Variant), An Enhanced Vector for Gene Transfer in Adults with Severe or Moderate-Severe Hemophilia B (ORAL10)
    Oral Session Title: Session 6: SLAM
    Date and Time: Friday February 7, 8:30 - 10:00 a.m. CET
     
  • Title: Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for Up To 4 Years Following AMT-060 Gene Therapy in Adults with Severe or Moderate-Severe Hemophilia B (Poster 100)
    Date and Time: Wednesday February 5, 6:30 - 7:30 p.m. CET
     
  • Title: Clearance of Vector DNA Following Systemic Administration of AAV5-hFIX Or AAV5-hFIX Padua In Patients with Severe or Moderate-Severe Hemophilia B (Poster 89)
    Date and Time: Wednesday February 5, 6:30 - 7:30 p.m. CET
     
  • Title: Prevalence and Affinity/Avidity Assessment of Pre-Existing NABS Against AAV1, 2, 5 And 8 Analyzed In the Serum Of 300 Healthy Donors (Poster 54)
    Date and Time: Wednesday February 5, 6:30 - 7:30 p.m. CET
     
  • Title: Seroprevalence Of Pre-Existing NABS Against AAV1, 2, 5, 6 And 8 in the South African Hemophilia B Patient Population (Poster 116)
    Date and Time: Wednesday February 5, 6:30 - 7:30 p.m. CET
     
  • Title: Evaluation of A Blood Coagulation Factor IX Variant That Functions Independently of Factor Viii as An Alternative Treatment of Hemophilia A
    Date and Time: Wednesday February 5, 6:30 - 7:30 p.m. CET
     
  • Title: Gene Therapy for People with Haemophilia B (PWHB): Development of A Cost-Effectiveness Model Framework (Poster 154)
    Date and Time: Wednesday February 5, 6:30 - 7:30 p.m. CET

About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, hemophilia A, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS: FOR MEDIA:
Maria E. Cantor  Eva M. Mulder Tom Malone
Direct: 339-970-7536 Direct: +31 20 240 6103 Direct: 339-970-7558
Mobile:  617-680-9452 Mobile: +31 6 52 33 15 79 Mobile:339-223-8541
m.cantor@uniQure.com e.mulder@uniQure.com  t.malone@uniQure.com 

To read more Press Release articles, click here.